DIABETIC NEUROPATHIC PAIN DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-52521 |   Uncategorized

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Diabetic Neuropathic Pain Drug Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET

7.1 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA DIABETIC NEUROPATHIC PAIN DRUG MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Astellas Pharma Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 AstraZeneca Plc

16.3 BioDelivery Sciences International, Inc.

16.4 Boehringer Ingelheim GmbH

16.5 Daiichi Sankyo Company, Limited

16.6 Dong-A Socio Group

16.7 Eli Lilly and Company

16.8 Glenmark Pharmaceuticals Ltd.

16.9 Hydra Biosciences, Inc.

16.10 Immune Pharmaceuticals Inc.

16.11 Laboratorios Del Dr. Esteve S.A.

16.12 Lohocla Research Corporation

16.13 Mertiva AB

16.14 Novaremed

16.15 Pharmaleads

16.16 RAPID Pharmaceuticals AG

16.17 Relmada Therapeutics, Inc.

16.18 Sphaera Pharma Pvt. Ltd.

16.19 Theravasc, Inc.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

AZD-5213
Clonidine Hydrochloride
Duloxetine Hydrochloride DR
E-52862
Filgrastim
GERPOOI
GRC-17536
Others

Market by Application :

Clinic
Hospital
Others

Companies

Astellas Pharma Inc.
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Mertiva AB
Novaremed
Pharmaleads
RAPID Pharmaceuticals AG
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.